Evidence map›Paper›PMID 31229437›Full record

ArticleEBioMedicine2019

Proteomic analysis of urinary extracellular vesicles reveal biomarkers for neurologic disease.

Shijie Wang, Kyoko Kojima, James A Mobley, Andrew B West

Open access · goldAbstract read
In one paragraph

Article in EBioMedicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 92 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
92citing papers in PubMed, 3 pooled it
6.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

92 citing papers in PubMed, 3 syntheses or guidelines pooled it, 153 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Guideline
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Cell-cell communication: new insights and clinical implications.Signal transduction and targeted therapy · 2024
    Review

32 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Shijie WangCenter for Neurodegeneration and Neurotherapeutics, Duke University, Durham, NC, USA.
Kyoko KojimaDepartment of Surgery, University of Alabama at Birmingham, Birmingham, AL, USA.
James A MobleyDepartment of Surgery, University of Alabama at Birmingham, Birmingham, AL, USA.
Andrew B WestCenter for Neurodegeneration and Neurotherapeutics, Duke University, Durham, NC, USA. Electronic address: Andrew.West@Duke.edu.
Duke University · USUniversity of Alabama at Birmingham · US

Funding

XRAY CRYSTALLOGRAPHYP30CA013148 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Robert S Welner · 1985 to 2026
$165.9M
Mechanisms of LRRK2 Mediated NeurotoxicityR01NS064934 · NINDS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI WEST, ANDREW B · 2010 to 2025
$6.3M
Exosome LRRK2 in Predicting Parkinson Disease PhenotypesU01NS097028 · NINDS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI WEST, ANDREW B · 2016 to 2018
$1.0M
Efficacies and Pharmacodynamic Assays for LRRK2 Small-Molecule InhibitorsR33NS097643 · NINDS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI WEST, ANDREW B · 2018 to 2019
$773k
NCI NIH HHS P30 CA013148NINDS NIH HHS R01 NS064934NINDS NIH HHS R33 NS097643NINDS NIH HHS U01 NS097028
6 · The paper itself

Abstract

backgroundExtracellular vesicles (EVs) harbor thousands of proteins that hold promise for biomarker development. Usually difficult to purify, EVs in urine are relatively easily obtained and have demonstrated efficacy for kidney disease prediction. Herein, we further characterize the proteome of urinary EVs to explore the potential for biomarkers unrelated to kidney dysfunction, focusing on Parkinson's disease (PD).

methodsUsing a quantitative mass spectrometry approach, we measured urinary EV proteins from a discovery cohort of 50 subjects. EVs in urine were classified into subgroups and EV proteins were ranked by abundance and variability over time. Enriched pathways and ontologies in stable EV proteins were identified and proteins that predict PD were further measured in a cohort of 108 subjects.

findingsHundreds of commonly expressed urinary EV proteins with stable expression over time were distinguished from proteins with high variability. Bioinformatic analyses reveal a striking enrichment of endolysosomal proteins linked to Parkinson's, Alzheimer's, and Huntington's disease. Tissue and biofluid enrichment analyses show broad representation of EVs from across the body without bias towards kidney or urine proteins. Among the proteins linked to neurological diseases, SNAP23 and calbindin were the most elevated in PD cases with 86% prediction success for disease diagnosis in the discovery cohort and 76% prediction success in the replication cohort.

interpretationUrinary EVs are an underutilized but highly accessible resource for biomarker discovery with particular promise for neurological diseases like PD.

Indexed as

AdultAgedAlzheimer DiseaseBiomarkersCalbindinsComputational BiologyExtracellular VesiclesFemaleHumansHuntington DiseaseMaleMiddle AgedParkinson DiseaseProteomeProteomicsQb-SNARE ProteinsBiomarkersCalbindinsProteomeQb-SNARE ProteinsQc-SNARE ProteinsSNAP23 protein, humanAlzheimer's diseaseBiomarkersExtracellular vesiclesNeurodegenerationParkinson's disease

Identifiers

PMID31229437
PMCPMC6642358
OpenAlexW2949785308

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.